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Introduction
The human gut microbiome consists of over 100 trillion micro-
bial cells, exceeding the amount of human cells by a factor of 10. 
Bacteria are found in various parts of the body including nasal 
passages, oral cavity, skin, urogenital system and the gastrointes-
tinal tract. The gut microbiota carries out a variety of valuable 
tasks for their human hosts; it assists in the development of in-
nate and adaptive immunity, serves as an energy source, and kills 
foreign organisms. (Dave, et al. 2012). The quality and composi-
tion of the gut microbiome depends largely on diet, medication 
and weight of its host. The microbiota is capable of secreting 
or altering the production of molecules that affect both weight 
gain or loss and fat mass. (Rosenbaum, et al. 2015) 
Colonization of the microbial microflora of the internal and 
external surfaces in a human begins at birth and is termed in-
digenous bacterial microflora. (Van der Waaij, 1989) The route 
of delivery when a baby is born determines which type of bac-
teria will develop.  Infants delivered vaginally have microbiota 
comparable to their own mother’s vagina, whereas infants born 
via Cesarean section develop microbes similar to the bacteria 
found on the skin surface. (Dominguez-Bello, et al. 2010) After 
birth, microbes develop and colonize, benefitting both them-
selves and their host, each contributing something vital to the 
other. (Van der Waaij 1989) For example, the anaerobic bacte-
ria in our distal gut breaks down complex polysaccharides and 
ferments the resulting monosaccharides into short chain fatty 
acids. This is a mutually beneficial relationship; the microbes live 
in a sheltered anaerobic environment and receive a rich assort-
ment of glycans while offering the host a source of carbon and 
energy. (Backhed, et al. 2005)
Of all the microbial communities being studied by human micro-
biome researchers, the gastrointestinal tract (GI) holds a prom-
ising future for the discovery of new concepts and therapies. 
The large colon holds the most abundant and diverse commu-
nities of microbes; it has both local and systemic effects on the 
body. (Dave et al. 2012)  The gut microbiota can be thought of as 
a “microbial organ placed within a host organ,” it plays vital roles 
in metabolism and immune system function. It is known that 
the microbial communities have a method of communication; 
they also can consume, store and redistribute energy. (Bakhed, 
et al. 2005)  
Fecal Microbiota Transplantation (FMT) is an FDA experimental 
drug targeted to treat Clostridium difficile associated diseases 
(CDAD). It has been successfully used to treat patients with ul-
cerative colitis (UC) and different forms of inflammatory bowel 
diseases (IBD).  Additionally, by comparing and analyzing the 
gut microbiome of lean and obese individuals, researchers have 
been able to hypothesize a cause for obesity and other weight 
issues. Using this knowledge, microbiologists can manipulate 
the microbiome and formulate a therapy to decrease obesity 
worldwide. This research can result in a new kind of pharmaco-
peia; implanting a more refined probiotic to combat infection, 
inflammation and dysbiosis.  
Methods and Materials
To investigate the mechanism of fecal bacteriotherapy and how 
it can be utilized to treat Clostridium difficile associated diseas-
es and other gastrointestinal disorders, many original research 
articles and reviews have been read. Touro College’s online da-
tabase was employed, particularly EBSCO, PubMed, ProQuest 
and Google scholar. Further research was done by perusing 
the footnotes and references in review papers to find original 
research. 
Discussion
Fecal Microbiota Transplantation
The indigenous microbiota is vital to the human host, yet it 
can be altered by various factors of modern day life, most 
commonly repeated doses of antibiotics. (Van der Waaij, 1989). 
Dethlefsen et al. tested the fecal microbiota of adults before 
and after oral administration of ciprofloxacin for five days using 
pyrosequencing. A rapid reduction in richness of bacterial phyla 
was seen, resulting in decreased diversity, fullness and balance 
in the microbiome. Four weeks following the completion of 
the antibiotic, the microbiota returned to baseline. However, 
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in some individuals, it took 6 months for the bacterial phyla to 
completely return to normal. (Dethlefsen et al., 2008)  Infectious 
diseases of the past were thought to be linked with bacteria ca-
pable of causing disease in a susceptible host. However, present 
day infectious diseases are linked to host interaction with po-
tentially pathogenic bacteria that make up the microflora of the 
digestive tract (Van der Waaij, 1989). A particular infection that 
results from a disruption of the gut microbiota is Clostridium 
difficile infection.  Clostridium difficile is an anaerobic, spore 
forming bacillus that produces 2 exotoxins that damage the in-
testinal mucosa. It is the most commonly recognized cause of 
anti-microbial associated diarrhea.  Clostridium difficile associ-
ated disease mainly affects the large colon, causing diarrhea and 
pseudomembranous colitis. If progressed, the infection can lead 
to toxic megacolon, sepsis and death (McDonald et al., 2006). 
The microbial colonies that regularly control the Clostridium 
difficile communities are inhibited and blocked by antibiotics. 
Because C. difficile spores are generally resistant to antibiotics, 
this allows them to germinate back into their vegetative state 
after antibiotic treatment has ended. If the remaining microbes 
in the intestine cannot get rid of the infection, Clostridium dif-
ficile can multiply and release the toxins that return the disease 
symptoms. (Bakken et al., 2011)
There are different treatments that exist for recurrent 
Clostridium difficile infection, many of which involve the use 
of stronger antibiotics, such as vancomycin and metronida-
zole. However, as Dr. Johan Bakken says, “the use of antibiot-
ics represents a double-edged sword by suppressing both the 
pathogen as well as the protective microbiota.” In other words, 
repeated and extended uses of antibiotics have negative effects 
on the natural gut flora. It is a possible risk factor for further 
infection due to the continuously altered state of gut microbes. 
(Bakken et al. 2011)
Another approach to treat recurrent Clostridium difficile in-
fection is to restore the damaged microbial communities using 
probiotics. Saccharomyces bouldarii is a yeast that colonizes in 
the colon within 3 days of ingestion, survives gastric acids of 
the stomach and is cleared from the colon once treatment is 
discontinued. The effectiveness of the probiotic as an add-on 
to antibiotics was tested in two trials. The treatment did not 
decrease recurrence rates in those with their first episode of 
Clostridium difficile infection but it did decrease the frequen-
cy of relapses in those with the recurrent infection. The sec-
ond trial showed effectiveness only in patients that were on 
a high dose of vancomycin. (McFarland et al., 1994) (Bakken 
et al., 2011) Thus, probiotics may have a role in treatment of 
Clostridium difficile infection, but their effectiveness is less than 
ideal. (Kelly, LaMont 2008)
Fecal Bacteriotherapy, or fecal microbiota transplantation 
(FMT), is an innovative and effective treatment for Clostridium 
difficile infection and other infections of the colon, including ul-
cerative colitis. It involves implanting stool from a healthy donor 
into a recipient’s diseased colon, thereby allowing a newer and 
healthier microbiome to develop and flourish. From the trials 
done and the case studies reported, it seems that recurrent 
Clostridium difficile infection can be cured with a single treat-
ment of FMT. The logic behind FMT is straightforward: strong 
antibiotics can cause an imbalance in the normal intestinal flora 
and reduce colonization resistance, which allows C. difficile to 
grow and cause symptoms of infection. With the introduction of 
healthy donor feces, the imbalance can be corrected, the cycle 
interrupted and the normal colon function returns. (Bakken, et 
al. 2011)
Although the first four patients to be treated with FMT in the 
20th century was in 1958 for pseudomembranous enterocolitis, 
(Bakken, et al. 2011) the use of fecal material as a treatment 
for diseases dates back more than 2500 years ago in ancient 
China. During the Dong-jin dynasty in the 4th century China, Ge 
Hong, a well-known doctor described the use of human fecal 
suspension by mouth for people suffering from severe diarrhea 
or food poisoning. This treatment was considered a medical 
miracle that brought patients back from the brink of death. In 
the 16th century, during the Ming dynasty, Li Shizen prescribed 
a series of fecal material doses to treat abdominal diseases that 
caused severe diarrhea, fever, pain, vomiting, and constipation. 
This treatment was called “yellow soup” for aesthetic reasons. 
(Zhang, et al. 2012)
Nowadays however, the procedure is done in a more sterilized 
manner and reported to have been successful via colonoscopy 
(Persky, Brandt 2010), nasogastric tube, (Aas, et al. 2003) naso-
duodenal tube, (van Nood, et al. 2013) and self-administered 
fecal enemas. (Silverman, et al. 2010) One method of implan-
tation was not found to be superior over the other. (Rohlke, 
Stollman 2012) 
Currently, the only FDA approved drug to treat C. difficile in-
fection is the antibiotic vancomycin, which is inadequate for pa-
tients suffering from recurrent CDI. It is estimated that 80% of 
patients treated with the standard antibiotic therapy are cured, 
however, the remaining 20% are likely to recur 3-28 days after 
discontinuation of antibiotics. Disease caused by C. difficile has 
been shown to increase the length of stay of patients by a mean 
of 7 days, incurring an additional $10,500 in health care charges 
for every infected patient. (McFarland, et al. 1994) Alternative 
treatments, including probiotics, surgery and administration of 
different antibiotics, have been suggested, but none were effec-
tive, safe and inexpensive. Fecal microbiota transplant seems to 
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fit the criteria of being inexpensive, highly effective and safe. In 
fact, a study done to compare 4 different treatments for CDAD; 
metronidazole, vancomycin, fidaxomicin and FMT demonstrat-
ed that FMT was the “most cost-effective strategy.” The incre-
mental cost-effectiveness ratio (ICER) was $17, 016 relative to 
oral vancomycin. (Konijeti, et al. 2014) It is “the only therapy 
that restores the phylogenic richness of the recipient’s intestinal 
microbiota without prolonging the perturbation of the normal 
microbiotic composition.” (Bakken, et al. 2011)  
A study comparing the fecal material of a patient before and 
after FMT illustrates the effectiveness of the transplant. Before 
FMT, the patient’s fecal material was composed of atypical bacte-
rial populations including Veillonella, Clostrudium, Lactobacillus, 
and Streptococcus. Two weeks after FMT, Bacteroidetes began 
to appear and four weeks after the transplant, the stool stud-
ies were culture negative for C. difficile. The recipient’s fecal 
bacterial composition greatly resembled the donor. Throughout 
the months following FMT the patient reported issues of loose 
stool, but those issues were resolved within two weeks without 
therapy. Six months later, the patient was completely cured from 
C. difficile infection. (Khoruts, et al. 2010)
Further data is needed to assess the effectiveness of FMT, yet 
given the promising data to date and anticipated research data 
on the intestinal microbiome, it seems to be the most reason-
able treatment for recurrent C. difficile infection (CDI). Bakken 
et al. put together a guideline for the proper administration of 
FMT. Included in the guideline is a detailed description of prima-
ry indication, donor selection and directions for preparing and 
administering the stool. Many trials and studies that involving 
FMT used this guideline as instructions on how to proceed. In 
order to be eligible for FMT, a patient either has to have recur-
rent or relapsing CDI with at least three episodes of mild-mod-
erate CDI and a failure of a 6-8 week taper with vancomycin. 
Patients on major immunosuppressive agents, decompensated 
liver cirrhosis or have had a recent bone marrow transplant 
cannot receive the fecal microbiota transplant as it may cause 
adverse effects. 
Currently, little or no data is available to suggest that any rea-
sons, other than the exclusion criteria based on medical history 
and laboratory testing, would recommend a specific donor over 
another. However, using intimate contacts as donors minimizes 
the risk of transmitting an infectious disease. Donors are inter-
viewed thoroughly and must answer a detailed questionnaire 
regarding their past medical history.  Donors are disqualified 
if they test positive for HIV, Hepatitis B or C infections or had 
exposure to HIV or viral hepatitis. Individuals that have high 
risk sexual behaviors, use illicit drugs, had tattoo or body pierc-
ing within 6 months or have a history of incarceration cannot 
donate stool for FMT. Once a donor passes the medical and lab-
oratory tests, their stool is screened for enteric pathogens such 
as  C. difficile toxin A and B,  fecal Giardia and Cryptosporidium 
antigens and Helicobacter pylori fecal antigen. (Bakken, et al. 
2011)
The stool donor may or may not take an osmotic laxative the 
night before the procedure. The stool should be used as soon as 
possible, preferably within 6 hours. The choice of diluents may 
vary among practitioners, but either preservative-free normal 
saline or 4% milk is combined with the stool in a household 
blender. It should be mixed until it reaches a homogenous slur-
ry consistency and filtered to remove particulate. The slurry 
stool mixture is to be used immediately. The optimal volume 
for transplantation has not been established yet; however if by 
nasogastric tube or via other routes from above, smaller vol-
umes (25-50 mL) should be used and if by colonoscopy or other 
routes from below, larger volumes (250-500 mL) may be used. 
(Bakken et. al. 2011) 
This is a basic outline on how a practitioner would administer 
fecal microbiota transplant. However, “practical and aesthetic 
barriers” have slowed down the widespread use of FMT, despite 
its success in dramatically resolving CDI after one treatment. 
Enrollment and screening of donors is a tedious process linked 
with substantial costs, thereby inhibiting the use of FMT in se-
vere situations. Youngster et al. suggests that by establishing a 
repository of prescreened frozen donor stool, this treatment 
may be more easily obtainable from a broader population. He 
conducted a trial to evaluate the efficacy of FMT in treating 
relapsing CDI in a pilot cohort of 20 patients, comparing colo-
noscopic and nasogastric tube administration. 
The donors for the study underwent extensive physical exam-
inations and general laboratory screening tests to ensure that all 
results were within normal range for age and sex. Renal function 
and electrolytes, complete blood count with differential, complete 
liver function tests and fecal occult blood testing were some of 
the tests that fecal donors underwent. All fecal donations were 
set aside for four weeks to allow retesting of donors for HIV and 
hepatitis B and C before the feces was inoculated. To facilitate ma-
nipulation of the fecal material, donors were asked to take milk 
of magnesia the day before the donation. The feces was mixed in 
a commercial blender with normal saline and then were passed 
through 4 sieves to get rid of any particulate. The final product 
was concentrated 3-fold by centrifugation and then resuspended 
in sterile saline with 10% glycerol added as a cytoprotectant. The 
resulting mixture was frozen at -80°C. Each filtered sample was 
calculated to have come from 41g of fecal material. Inocula were 
stored frozen for up to 156 days and thawed in a 37°C water 
bath, then kept on ice until delivery. 
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Patients were ordered to stop taking antibiotics for 2 days be-
fore the procedure. Recipients designated for a colonoscopic 
administration underwent a standard bowel preparation with 
4 liters of polyethylene glycol electrolyte solution. Then, 90 cc 
of the thawed inoculum was placed in the right colon via en-
doscopy. The fecal material was further diluted to 250 cc for 
adults and 160 cc for pediatric recipients. Patients were given 
a single dose of loperamide at the time of the procedure in 
order to retain the material for as long as possible. The pa-
tients assigned to nasogastric tube administration were given 
omeprazole orally for 2 days before the procedure, to ensure 
that the fecal bacteria will not be affected by the acids in the 
stomach. After inserting the nasogastric tube, 90 cc of inoculum 
was administered. In order to minimize vomiting and aspiration, 
the inoculum was not diluted. (Youngster, et al. 2014)
The goal of the trial was the clinical resolution of diarrhea off 
antibiotics for C. difficile infection, without a recurrent episode 
within 8 weeks. Patients who showed no improvement were 
offered a second FMT by their preferred route of administra-
tion, using the same donor inoculum to minimize exposure to 
infectious agents. 
Of the 20 patients in both study arms, 14 were cured after the 
first FMT; 8 of them were in the colonoscopy group and 6 in the 
nasogastric tube group. One patient refused a second transplant 
but the remaining 5 patients were given a second infusion via 
NGT using feces from their original donors. Four patients were 
cured after the second FMT, resulting in an overall cure rate of 
90%. No patient relapsed within the 8 week period following 
the initial cure. 
There were some serious adverse effects that were deemed 
unrelated to the trial by investigators and the Institutional re-
view board, which may have been caused by the poor health 
of the patients with recurrent CDI. 2 patients died; one from 
an obstructive pulmonary disease and another from metastatic 
laryngeal cancer. A third patient was diagnosed with adenocar-
cinoma of the esophagus and a fourth (treated via NGT) was 
hospitalized for Fourier gangrene. 
This trial demonstrated that the transplantation of unrelated 
frozen donor stool is effective in treating recurrent CDI with 
an overall cure rate of 90%. Additionally, NGT appears to be a 
feasible route of administration for elderly patients with the 
infection. One 89 year old female patient had 16 documented 
cases of CDI in the previous 15 months. She was hospitalized 
4 times and placed on the intensive care unit twice due to the 
infection. After two infusions, she was cured and was free from 
any symptoms of the disease off treatment for 12 months. 
(Youngster, et. al. 2014)  
Seeing the success with frozen inocula, Youngster et al. direct-
ed another study evaluating the effectiveness of oral capsulized 
frozen fecal microbiota transplantation in treating relapsing C. 
difficile infection. The donors were thoroughly screened, as 
described in the previous study (and the guideline by Bakken, 
et al. 2011) and similar processing of the fecal material took 
place. To ensure that the acidic environment of the stomach will 
not destroy the capsule, commercially available acid-resistant 
hypromellose capsules were used. The stability of the capsules 
was tested by mimicking the acidic environment of the stomach. 
Trypan blue filled capsules were used, at a temperature of 37°C 
and a pH of 3 or less, and the capsules were stable for 115 
minutes before the dye was released. 
From July 2013 through January 2014, a total of 20 patients 
were treated using stool obtained from four donors. The recip-
ients followed up six months later in July 2014. The goal of the 
study was the clinical resolution of diarrhea, while not receiving 
antibiotic for C. difficile, without relapse within 8 weeks. 
The procedure went as follows: each patient was given 15 cap-
sules, directly from an investigator on 2 consecutive days. 2 days 
prior to FMT, patients were ordered to stop all antibiotics. They 
were asked to fast 4 hours prior to and 1 hour post taking the 
capsule for both days. If there was no improvement after 72 
hours, patients were retested and offered another treatment 
for positive test results.   
From the 20 patients treated, 14 had clinical resolution of diar-
rhea after the first FMT. The remaining 6 patients were retreat-
ed 7 days after the first procedure. 5 of the 6 had resolution of 
diarrhea after the second FMT, however one patient relapsed 
within the 8 week follow up time period. Thus the overall rate 
of diarrheal resolution was 90%. (Youngster et. al. 2014) 
Fecal microbiota transplantation used to treat C. difficile infec-
tion is a highly effective, safe and inexpensive method as de-
scribed studies and research. Very few, if not any, complications 
were caused by FMT. The fecal material can be manipulated and 
can be transplanted as a liquid via NGT or colonoscopy and can 
also be ingested as a capsule. FMT is currently an FDA experi-
mental drug and therefore the trials and studies are with small 
samples and lack of placebo or other trial to compare. Granted, 
the trials and studies done are encouraging, however this may 
be due to the small sample size. Furthermore, even with careful 
screening, there is a potential risk of transmission of infections 
via microbiota transplantation. Larger studies would be needed 
to confirm these outcomes and to evaluate long-term safety 
and effectiveness. (Youngster et. al 2014)
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Fecal Microbiota Transplant for Ulcerative Colitis
Encouraged by the success for fecal microbiota transplant in 
the treatment of C. difficile infection, researchers looked to 
other conditions related to GI microbial imbalance, such as 
inflammatory bowel disease (IBD), obesity and diabetes mel-
litus. (Borody, et al. 2103) Inflammatory bowel diseases are 
thought to be caused by an overall community dysbiosis rath-
er than a single underlying pathogen. In patients with IBD, an 
increase in Actinobacteria and Proteobacteria and a decrease 
of Lachnospiraceae, Bacteroidetes, Clostridium leptum, and 
Bifidobacteria are observed. (Clemente, et. al. 2012)
Ulcerative colitis (UC), a type of IBD, is a chronic devastating 
inflammatory bowel disease that affects the large intestine. 
Unfortunately, the current medications used to treat UC have 
significant adverse effects; they mainly target the inflammation 
without focusing on the dysbiosis. (Kunde, et al. 2013)   The 
colonic microbiome in UC patients lacks diversity and is dys-
functional. The cause of inflammation of the colon in UC is 
hypothesized to be caused by inappropriate stimulation of the 
innate mucosal immune system because of dysbiosis in a ge-
netically susceptible individual. Borody et al. asks the following 
question: C. difficile infection causes reduced microbial diversity 
which results in symptoms of colitis; if FMT can reverse this, 
perhaps a similar treatment can be used to treat ulcerative coli-
tis? (Borody, et al. 2013)  
Borody et. al. conducted a trial assessing the clinical, histological 
and colonoscopic effects of “human probiotic infusion” (HPI), or 
fecal material transplant in six selected patients with ulcerative 
colitis. All patients had suffered from severe recurrent symp-
toms of UC and each, respectively, were on series of moderate 
to high dose steroids and anti-inflammatory medications. The 
donors were chosen by the recipient patients and screened 
thoroughly to prevent any transmission of parasites or bacterial 
pathogens. The feces (200–300 g) was diluted in 200 to 300 
mL normal saline and administered to the patient via retention 
enema within 10 minutes of its preparation. This process was 
repeated daily for 5 consecutive days. One week following HPI, 
some symptoms of ulcerative colitis had resolved in several pa-
tients.  A complete reversal of symptoms was achieved in all 
patients 4 months post HPI, by which all other UC medications 
had been discontinued. From 1 to 13 years later, patients re-
mained asymptomatic with a healthy colonoscopic appearance 
and normal histology.
However, the pathogenesis of UC is unknown since it is char-
acterized by persistent inflammation. It is suggested that the 
disease is driven by a chronic infection caused by the absence 
of vital luminal anaerobes.  If the ability of the normal flora to 
resist colonization by pathogens is hindered, for example, by 
previous antibiotic use, the numbers of protective anaerobes in 
the colon, such as Bacteroides, decrease. This would allow the 
establishment of other pathogenic anaerobes or spore bearing 
bacteria and a form of recurrent, chronic colitis. The persistence 
of UC may be due to the implantation of spores in the mucosal 
surface, analogous to Clostridium difficile infection. Antibiotics 
may help briefly but are unlikely to be curative because the 
spores are not eliminated. (Borody et. al. 2003) 
Kunde et. al. conducted a pilot study to evaluate the efficiency 
and safety of fecal microbiota transplantation in children with 
ulcerative colitis. Ten children, ages 7 to 21 with mild to mod-
erate UC according to the pediatric ulcerative colitis activity 
index (PUCAI) were enrolled in the study. Clinical response and 
improvement was defined as decrease in PUCAI by more than 
15 points on the index. A decrease in PUCAI to less than 10 
points was considered clinical remission. Each donor produced 
a 90 gram stool sample every day which was blended with 250 
mL normal saline and filtered through 2 gauze pieces to remove 
sediments. It was then separated into 4 aliquots of 60 mL each 
and kept in a warm water bath (37°) until administration. Each 
patient received FMT as retention enema for 1 hour (60-mL 
enema every 15 minutes) daily for 5 days. One subject however, 
was not able to tolerate the retention enema for 3 consecutive 
days and was therefore not included in the results. Within one 
week following the procedure, 7 of the 9 subjects (78%) showed 
clinical response. Four weeks after FMT, six of the nine patients 
(67%) maintained the clinical response. However, 3 of the nine 
subjects (33%) went into clinical remission one week following 
FMT. All of the adverse events related to FMT, besides fever, 
were self-limiting, and did not require intervention from health 
care providers. The majority of them were similar to subjects’ 
baseline symptoms of UC such as bloating and diarrhea.
The dramatic response to FMT after one week was not achieved 
in all subjects, perhaps due to the severity or duration of the 
disease, or the ability to retain larger FMT volumes for longer 
periods. Using FMT via fecal enema to treat UC in children is 
feasible, as proved in the trial. However, the sample size was small 
and therefore limits future indication. In order to improve FMT a 
standardization procedure would need to be arranged for donor 
selection and ideal routes of administration. (Kunde, et al. 2013)
The Gut Microbiota and Obesity
The World Health Organization (WHO) reports that in 2014, 
more than 1.9 billion adults, 18 years and older were overweight 
and of these, over 600 million were obese. Obesity is a growing, 
worldwide epidemic that has been accompanied by increases in 
obesity related disorders, including type II diabetes, hypertension 
and nonalcoholic fatty liver disease. Much emphasis has been 
placed on the dietary excess or host genes in obese individuals. 
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Yet, in addition to increased calories or shifts in host metabolism, 
the composition of the intestinal microbiota can contribute to 
the progression of obesity. Both diet induced obesity and gene in-
duced obesity have microbe independent and microbe dependent 
pathways. (Baackhed et al. 2004, Cox, Blaser 2013)
A study was done to investigate the effect that diet has on shap-
ing the gut microbiome. The fecal material of 15 European chil-
dren and that of 14 children from a rural African village, Bukina 
Faso were compared and tested with 16S rRNA sequencing, 
and biochemical analysis. The goal of the study was to explore 
three questions: the split of bacterial diversity between the two 
populations, the connection between the gut microbiota and 
diet, and the distribution of well-known bacterial pathogens 
within the two populations given the different hygienic and geo-
graphic conditions.
The diet of Bukina Faso children is mostly vegetarian; rich in 
plant polysaccharides, starch and fiber and low in fat and ani-
mal protein. All the food was grown and harvested nearby the 
village by women.  The European children were eating a typical 
Western diet high in animal protein, sugar, starch and fat and 
low in fiber. A dataset consisting of 438, 219 of filtered, high 
quality, classifiable 16S rRNA was generated. Of all of the se-
quences in all the Bukina Faso and European samples 92.4% 
were found to belong to the most populated bacterial phyla: 
Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. 
However, it was the proportions that stood out: Actinobacteria 
and Bacteroidetes were more abundant in the Bukina Faso chil-
dren than the European children 10.1% versus 6.7% and 57.7% 
versus 22.4%, whereas Firmicutes and Proteobacteria were rep-
resented more in EUROPEAN than BUKINA FASO children, 
63.7% versus 27.3% and 6.7% versus 0.8%. Since Prevotella, 
Xylanibaeter (Bacteroidetes) and Treponema (Spirochaetes) 
were exclusively found in the Bukina Faso children. De Filippo 
et. al. hypothesized that these 3 genera could be a result of high 
fiber intake due to the environmental factors distinguishing the 
two populations (diet, hygiene, climate and geography). Perhaps 
these three groups contribute to the extraction of metabol-
ic energy from ingested plant polysaccharides. It is reasonable 
to deduce that the increase in the Firmicutes to Bacteroidetes 
(F/B) ratio in European children possibly triggered by their 
high-calorie diet might predispose them to future obesity. This 
Firmicutes/Bacteroidetes ratio may also be considered a useful 
obesity biomarker. (De Filippo, et al. 2010)
A study done by Turnbaugh et al.  further demonstrates the 
effect of diet on the gut microbiota. Mice raised in a germ free 
environment without any exposure to microbes, and then col-
onized at specific life stages with different microbial communi-
ties are referred to as gnotobiotic animals. Adult human fecal 
microbiota was transplanted into the recipient mice to establish 
a stable gut community similar their donors. An aliquot of the 
fecal dilution was introduced by gavage to the 15 recipient mice. 
These mice were maintained on a low fat plant polysaccharide 
(LF/PP) rich diet and fecal samples were collected 1 day, 1 week 
and 1 month after colonization. Half of the mice were then 
switched to a high-sugar, high-fat Western diet. The LF/PP and 
Western diet were maintained for 2 additional months, after 
which the mice were killed. Results showed that when the diet 
of the mice were switched from a LF/PP regimen to a high-
fat, high sugar “Western” diet the structure of the microbiota 
was shifted within a single day. The representation of metabolic 
pathways in the microbiome were changed and the microbi-
ome gene expression was altered. The mice fed a Western diet 
had an increased representation of the Erysipelotrichi class of 
bacteria within the Firmicutes phylum relative to mice fed the 
LF/PP diet. In mice that consumed a Western diet, the Bacilli, 
another class of the Firmicutes was abundant and a significant 
decrease in member of Bacteroidetes was found. These mice 
increased adiposity, demonstrating that this trait is transmissible 
via microbiota transplantation. Using germ free mice, research-
ers were able to see a clear correlation between the foods the 
mice were fed and its effect on the composition of their gut 
microbiota. Gnotobiotic technology is a promising tool for dis-
covering new classes of probiotics that affect nutrient harvest in 
a given diet.  (Turnbaugh, et al.2008) 
A study comparing the fecal material of 31 adult female monozy-
gotic and 23 dizygotic twin pairs and their mothers, concordant 
for obesity or leanness, was performed, to address how host 
genotype, environmental exposures and host adiposity influence 
the gut microbiome. All twins were 25-32 years old of European 
or African ancestry. Analysis of 16S rRNA datasets produced 
by the three PCR-based methods, plus shotgun sequencing of 
community DNA, revealed a lower proportion of Bacteroidetes 
and a higher proportion of Actinobacteria in obese versus lean 
Europeanropean and African individuals. Overall, across many 
methods, obesity was associated with a decrease in diversity 
of the gut microbiota. “This reduced diversity suggests an anal-
ogy: the obese gut microbiota is not like a rainforest or reef, 
which are adapted to high energy flux and are highly diverse, 
but rather may be more like a fertilizer runoff where a reduced 
diversity microbial community blooms with abnormal energy 
input.” (Turnbaugh, et al. 2009) 
There is an interesting case study regarding the transmission of 
“obese bacteria.” A 32 year old female patient with recurrent 
CDI elected to undergo FMT after many failed antibiotic thera-
pies. Around the same time, she tested positive for Helicobacter 
pylori. 
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The patient chose her 16 year old daughter, who was approxi-
mately 140 pounds to be her stool donor, and, subsequently, her 
weight increased to 170 pounds. The patient herself was 136 
pounds at the time of the transplant. The patient was retreat-
ed for H. pylori with metronidazole, tetracycline, bismuth and 
proton pump inhibitor, and two weeks later she had the FMT. 
Six hundred cc. of the suspension of the donor stool in sterile 
water was infused through a colonoscope. The patient dra-
matically improved after the procedure and CDI did not recur. 
However, 16 months later, the patient presented again, and re-
ported an unintentional weight gain of 34 pounds. Despite a 
medically supervised liquid protein diet and exercise program 
she had been unable to lose weight. Her weight continued to 
climb despite the diet and exercise and at 36 months post FMT 
she weighed 177 pounds. 
Alang and Kelly offer a several of hypotheses to explain the 
rapid weight gain following FMT.  There is a known link between 
H. pylori treatment and weight gain, resulting from the increase 
in appetite after the suppression of the bacteria. Yet, the patient 
was never obese before FMT and the fact that the stool donor 
also gained weight leads to the possibility that her obesity re-
sulted from the transplant (Alang, Kelly 2014). 
This hypothesis is supported in a study testing the fecal ma-
terial of twins discordant for obesity. This experiment offers 
an opportunity to examine connections between obesity and 
its associated metabolic disorders, diet, and the gut microbi-
ota. Ridaura et al. conducted a study by transplanting the fecal 
material of twins discordant for obesity into mice in order to 
replicate the donors’ microbiota community in the colon. The 
impact of these differences on the body composition and met-
abolic phenotypes were able to be detected, and the effects 
of diet-by-microbiota interactions analyzed. The mice harboring 
the transplanted microbiomes from the obese twins exhibited 
higher expression of microbial genes involved in detoxification 
and stress responses, in biosynthesis of cobalamin and metab-
olism of essential amino acids. In contrast, the transplanted 
microbiomes from lean co-twins exhibited higher expression 
of genes involved in digestion of plant-derived polysaccharides, 
fermentation to butyrate and propionate. The results suggest 
that the transplanted microbiota of the lean co-twins had great-
er capacity to breakdown and ferment polysaccharides than the 
microbiota of their obese co-twins. (Ridaura, et al. 2013)
From these studies, it is evident that the gut microbiota reflects 
the health, diet and metabolism of its host. It seems that the com-
position of the phyla that make up the gut microbiome in healthy 
individuals is properly balanced. However, a disrupted microbiome 
can contribute to obesity by altering energy extraction from food. 
Conclusion
By transplanting stool from a healthy donor into a recipient’s 
diseased colon via fecal bacteriotherapy, a newer and healthier 
microbiome can flourish and the function of the large intestine 
can be restored. Fecal microbiota transplant has been proven 
by many clinical trials to be a safe, effective and inexpensive 
procedure. FMT has been successful in treating many cases C. 
difficile infection, as well as ulcerative colitis and has a promising 
future in the field of diet and obesity. The stool material can be 
readily administered in different ways, as a slurry consistency 
administered via colonoscopy or nasogastric tube, or packaged 
in a pill and taken orally; this therapy is easily accessible to al-
most all populations. 
However, one potential drawback of FMT is the small sample 
size in many of the clinical trials done. Additionally, fecal bacte-
riotherapy may not be the ideal treatment for every individual 
suffering with GI tract disorders, for example, it may not be 
ideal in immunocompromised patients. However, FMT is an FDA 
approved drug and will undergo further standardization regard-
ing donors and the preparations and administration of the stool. 
The future of the gut microbiota related treatment is an active 
topic of research; much is anticipated from this exploration into 
the microbiome. 
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